| 40352-7 |
MT-ND5 gene.m.13513G>A |
PrThr |
Bld/Tiss |
Pt |
Ord |
Molgen |
|
ACTIVE |
MT-ND5 gene m.13513G>A [Presence] in Blood or Tissue by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
40352-7 |
|
Molgen |
|
|
Both |
|
|
|
0 |
MT-ND5 m.13513G>A Bld/T Ql |
|
|
|
N |
|
Blood; D393N; Genetics; Heredity; Heritable; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; MTND5; MT-ND5 m.13513G>A; NADH dehydrogenase, subunit 5 (complex I) gene; NADH-ubiquinone oxidoreductase chain 5 gene; Ordinal; PCR; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
2.15 |
|
|
|
|
|
|
|
|
|
|
Changed Component part from c.G13513A to m.13513G>A since variant is located on a mitochondrial sequence and to harmonize with HGVS nomenclature guidelines.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 40353-5 |
MT-ND6 gene.m.14484T>C |
PrThr |
Bld/Tiss |
Pt |
Ord |
Molgen |
|
ACTIVE |
MT-ND6 gene m.14484T>C [Presence] in Blood or Tissue by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
40353-5 |
|
Molgen |
|
|
Both |
|
|
|
0 |
MT-ND6 m.14484T>C Bld/T Ql |
|
|
|
N |
|
Blood; Genetics; Heredity; Heritable; Inherited; M64V; Met64Val; Mitochondrially encoded NADH dehydrogenase 6; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; MTND6; MT-ND6 m.14484T>C; NADH dehydrogenase, subunit 6 (complex I) gene; NADH-ubiquinone oxidoreductase chain 6 gene; Ordinal; PCR; Point in time; PR; QL; Qual; Qualitative; Random; Screen; T14484C; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
2.15 |
|
|
|
|
|
|
|
|
|
|
Changed Component part from c.T14484C to m.14484T>C since variant is located on a mitochondrial sequence and to harmonize with HGVS nomenclature guidelines.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 40354-3 |
MT-ND1 gene.m.3460G>A |
PrThr |
Bld/Tiss |
Pt |
Ord |
Molgen |
|
ACTIVE |
MT-ND1 gene m.3460G>A [Presence] in Blood or Tissue by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
40354-3 |
|
Molgen |
|
|
Both |
|
|
|
0 |
MT-ND1 m.3460G>A Bld/T Ql |
|
|
|
N |
|
Blood; Genetics; Heredity; Heritable; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; MTND1; MT-ND1 m.3460G>A; NADH dehydrogenase, subunit 1 (complex I) gene; NADH-ubiquinone oxidoreductase chain 1 gene; Ordinal; PCR; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
2.15 |
|
|
|
|
|
|
|
|
|
|
Changed Component part from c.G3460A to m.3460G>A since variant is located on a mitochondrial sequence and to harmonize with HGVS nomenclature guidelines.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 40355-0 |
Cotinine |
PrThr |
Hair |
Pt |
Ord |
|
|
ACTIVE |
Cotinine [Presence] in Hair |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
40355-0 |
|
|
|
|
Both |
|
|
|
0 |
Cotinine Hair Ql |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Har; Nicotine metabolite; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen |
2.56 |
2.15 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 40356-8 |
Creatinine |
SRat |
Dial fld |
24H |
Qn |
|
|
ACTIVE |
Creatinine [Moles/time] in 24 hour Dialysis fluid |
|
MIN |
DefinitionDescription |
|
|
umol/d |
|
|
|
|
|
|
CHEM |
|
40356-8 |
|
|
|
|
Both |
|
|
|
0 |
Creat 24h Dial fld-sRate |
|
|
|
N |
|
1 day; 24 hours; 24HR; Chemistry; CR; Crea; Creat; Diaf; Dialysate; Dialysis fluid; Kidney; Nephrology; QNT; Quan; Quant; Quantitative; Renal; sRate; Substance Rate |
2.7 |
2.15 |
|
|
|
|
|
|
|
umol/(24.h) |
|
|
|
0 |
| 40357-6 |
Creatinine |
SRat |
Body fld |
24H |
Qn |
|
|
ACTIVE |
Creatinine [Moles/time] in 24 hour Body fluid |
|
MIN |
DefinitionDescription |
|
|
umol/d |
|
|
|
|
|
|
CHEM |
|
40357-6 |
|
|
|
|
Both |
|
|
|
0 |
Creat 24h Fld-sRate |
|
|
|
N |
|
1 day; 24 hours; 24HR; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Chemistry; CR; Crea; Creat; Fl; Fld; FLU; Fluid; Kidney; Nephrology; QNT; Quan; Quant; Quantitative; Renal; sRate; Substance Rate |
2.7 |
2.15 |
|
|
|
|
|
|
|
umol/(24.h) |
|
|
|
0 |
| 40358-4 |
Desipramine |
PrThr |
Gast fld |
Pt |
Ord |
|
|
ACTIVE |
Desipramine [Presence] in Gastric fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
40358-4 |
|
|
|
|
Both |
|
|
|
0 |
Desipramine Gast Ql |
|
|
|
N |
|
Desi; Desip; Desipra; Desmethylimipramine; DRUG/TOXICOLOGY; Drugs; GAST; Gastric contents; Gastric fluid; Imipramine metabolite; Norpramin; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen |
2.56 |
2.15 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 40359-2 |
Dextromethorphan |
PrThr |
XXX |
Pt |
Ord |
|
|
ACTIVE |
Dextromethorphan [Presence] in Specimen |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
40359-2 |
|
|
|
|
Both |
|
|
|
0 |
D-methorphan Spec Ql |
|
|
|
N |
|
Dextro-methorphan; D-methorphan; DRUG/TOXICOLOGY; Drugs; Misc; Miscellaneous; Ordinal; Other; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; To be specified in another part of the message; Unspecified |
2.73 |
2.15 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 4036-0 |
Stanozolol |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Stanozolol [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
4036-0 |
|
|
|
|
Both |
|
|
|
0 |
Stanozolol Ur Ql |
|
|
|
|
|
Androstanazole; DRUG/TOXICOLOGY; Drugs; Methylstanazole; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Stromba; Strombaject; UA; UR; Urn; Winstrol |
2.73 |
1 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 40360-0 |
Follitropin^15M post dose triple bolus |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Follitropin [Units/volume] in Serum or Plasma --15 minutes post dose triple bolus |
|
MIN |
DefinitionDescription |
|
|
IU/L;mIU/mL |
|
|
|
|
|
|
CHAL |
|
40360-0 |
|
|
|
|
Observation |
|
|
|
0 |
FSH 15M p Triple Bolus SerPl-aCnc |
|
|
|
N |
|
15M p Triple Bolus; After; Arbitrary concentration; CHEMISTRY.CHALLENGE TESTING; Follicle stimulating hormone; FSH; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tri; Trip |
2.7 |
2.15 |
|
|
|
|
|
|
|
m[IU]/mL |
|
|
|
0 |
| 40361-8 |
Follitropin^1H post dose triple bolus |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Follitropin [Units/volume] in Serum or Plasma --1 hour post dose triple bolus |
|
MIN |
DefinitionDescription |
|
|
IU/L;mIU/mL |
|
|
|
|
|
|
CHAL |
|
40361-8 |
|
|
|
|
Observation |
|
|
|
0 |
FSH 1h p Triple Bolus SerPl-aCnc |
|
|
|
N |
|
1 hour; 1.0Hr; 1h p Triple Bolus; 60 min; 60 minutes; 60M; 60min; After; Arbitrary concentration; CHEMISTRY.CHALLENGE TESTING; Follicle stimulating hormone; FSH; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tri; Trip |
2.7 |
2.15 |
|
|
|
|
|
|
|
m[IU]/mL |
|
|
|
0 |
| 40362-6 |
Follitropin^20M post dose triple bolus |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Follitropin [Units/volume] in Serum or Plasma --20 minutes post dose triple bolus |
|
MIN |
DefinitionDescription |
|
|
IU/L;mIU/mL |
|
|
|
|
|
|
CHAL |
|
40362-6 |
|
|
|
|
Observation |
|
|
|
0 |
FSH 20M p Triple Bolus SerPl-aCnc |
|
|
|
N |
|
20M p Triple Bolus; After; Arbitrary concentration; CHEMISTRY.CHALLENGE TESTING; Follicle stimulating hormone; FSH; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tri; Trip |
2.7 |
2.15 |
|
|
|
|
|
|
|
m[IU]/mL |
|
|
|
0 |
| 40363-4 |
Follitropin^2H post dose triple bolus |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Follitropin [Units/volume] in Serum or Plasma --2 hours post dose triple bolus |
|
MIN |
DefinitionDescription |
|
|
IU/L;mIU/mL |
|
|
|
|
|
|
CHAL |
|
40363-4 |
|
|
|
|
Observation |
|
|
|
0 |
FSH 2h p Triple Bolus SerPl-aCnc |
|
|
|
N |
|
120 min; 120 minutes; 120min; 2 hours; 2h p Triple Bolus; After; Arbitrary concentration; CHEMISTRY.CHALLENGE TESTING; Follicle stimulating hormone; FSH; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tri; Trip |
2.7 |
2.15 |
|
|
|
|
|
|
|
m[IU]/mL |
|
|
|
0 |
| 40364-2 |
Follitropin^30M post dose triple bolus |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Follitropin [Units/volume] in Serum or Plasma --30 minutes post dose triple bolus |
|
MIN |
DefinitionDescription |
|
|
IU/L;mIU/mL |
|
|
|
|
|
|
CHAL |
|
40364-2 |
|
|
|
|
Observation |
|
|
|
0 |
FSH 30M p Triple Bolus SerPl-aCnc |
|
|
|
N |
|
30M p Triple Bolus; After; Arbitrary concentration; CHEMISTRY.CHALLENGE TESTING; Follicle stimulating hormone; FSH; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tri; Trip |
2.7 |
2.15 |
|
|
|
|
|
|
|
m[IU]/mL |
|
|
|
0 |
| 40365-9 |
Follitropin^pre dose triple bolus |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Follitropin [Units/volume] in Serum or Plasma --pre dose triple bolus |
|
MIN |
DefinitionDescription |
|
|
IU/L;mIU/mL |
|
|
|
|
|
|
CHAL |
|
40365-9 |
|
|
|
|
Observation |
|
|
|
0 |
FSH pre Triple Bolus SerPl-aCnc |
|
|
|
N |
|
Arbitrary concentration; Before; CHEMISTRY.CHALLENGE TESTING; Follicle stimulating hormone; FSH; Pl; Plasma; Plsm; Point in time; pre Triple Bolus; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tri; Trip |
2.7 |
2.15 |
|
|
|
|
|
|
|
m[IU]/mL |
|
|
|
0 |
| 40366-7 |
Glucose |
SRat |
Body fld |
24H |
Qn |
|
|
ACTIVE |
Glucose [Moles/time] in 24 hour Body fluid |
|
MIN |
DefinitionDescription |
|
|
mmol/24 H |
|
|
|
|
|
|
CHEM |
|
40366-7 |
|
|
|
|
Both |
|
|
|
0 |
Glucose 24h Fld-sRate |
|
|
|
N |
|
1 day; 24 hours; 24HR; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Chemistry; Fl; Fld; FLU; Fluid; Glu; Gluc; Glucoseur; QNT; Quan; Quant; Quantitative; sRate; Substance Rate |
2.7 |
2.15 |
|
|
|
|
|
|
|
mmol/(24.h) |
|
|
|
0 |
| 40367-5 |
Heptacarboxylate |
SRat |
Urine |
24H |
Qn |
|
|
ACTIVE |
Heptacarboxylate [Moles/time] in 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
nmol/24 H |
|
|
|
|
|
|
CHEM |
|
40367-5 |
|
|
|
|
Both |
|
|
|
0 |
Heptacarboxylate 24h Ur-sRate |
|
|
|
N |
|
1 day; 24 hours; 24HR; Chemistry; Heptacarbox; QNT; Quan; Quant; Quantitative; sRate; Substance Rate; UA; UR; Urn |
2.7 |
2.15 |
|
|
|
|
|
|
|
mmol/(24.h) |
|
|
|
0 |
| 40368-3 |
Hexacarboxylate |
SRat |
Urine |
24H |
Qn |
|
|
ACTIVE |
Hexacarboxylate [Moles/time] in 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
nmol/24 H |
|
|
|
|
|
|
CHEM |
|
40368-3 |
|
|
|
|
Both |
|
|
|
0 |
Hexacarboxylate 24h Ur-sRate |
|
|
|
N |
|
1 day; 24 hours; 24HR; Chemistry; Hexacarbox; QNT; Quan; Quant; Quantitative; sRate; Substance Rate; UA; UR; Urn |
2.7 |
2.15 |
|
|
|
|
|
|
|
nmol/(24.h) |
|
|
|
0 |
| 40369-1 |
HYDROmorphone |
PrThr |
Gast fld |
Pt |
Ord |
|
|
ACTIVE |
HYDROmorphone [Presence] in Gastric fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
40369-1 |
|
|
|
|
Both |
|
|
|
0 |
HYDROmorphone Gast Ql |
|
|
|
N |
|
Addiction; Dihydromorphinone; Dilaudid; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GAST; Gastric contents; Gastric fluid; Hydromorphinone; Illicit; Ordinal; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Screen |
2.56 |
2.15 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 4037-8 |
Stanozolol |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Stanozolol [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
4037-8 |
|
|
|
|
Both |
|
|
|
0 |
Stanozolol Ur-mCnc |
|
|
|
Y |
|
Androstanazole; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Methylstanazole; Point in time; QNT; Quan; Quant; Quantitative; Random; Stromba; Strombaject; UA; UR; Urn; Winstrol |
2.42 |
1 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 40370-9 |
Imipramine |
PrThr |
Gast fld |
Pt |
Ord |
|
|
ACTIVE |
Imipramine [Presence] in Gastric fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
40370-9 |
|
|
|
|
Both |
|
|
|
0 |
Imipramine Gast Ql |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; GAST; Gastric contents; Gastric fluid; Imipra; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tofranil |
2.56 |
2.15 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 40371-7 |
Isoniazid |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Isoniazid [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
40371-7 |
|
|
|
|
Both |
|
|
|
0 |
Isoniazid Ur Ql |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Hyzyd; INH; Isoniaz; Isoniazide; Nudrazod; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.56 |
2.15 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 40372-5 |
Isopropanol |
PrThr |
Gast fld |
Pt |
Ord |
|
|
ACTIVE |
Isopropanol [Presence] in Gastric fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
40372-5 |
|
|
|
|
Both |
|
|
|
0 |
Isopropanol Gast Ql |
|
|
|
N |
|
2-propanol; c615; DRUG/TOXICOLOGY; Drugs; GAST; Gastric contents; Gastric fluid; Isopropyl alcohol; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen |
2.56 |
2.15 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 40373-3 |
Lutropin^15M post dose triple bolus |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Lutropin [Units/volume] in Serum or Plasma --15 minutes post dose triple bolus |
|
MIN |
DefinitionDescription |
|
|
mIU/mL;IU/L |
|
|
|
|
|
|
CHAL |
|
40373-3 |
|
|
|
|
Observation |
|
|
|
0 |
LH 15M p Triple Bolus SerPl-aCnc |
|
|
|
N |
|
15M p Triple Bolus; After; Arbitrary concentration; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; ICSH; Interstitial cell-stimulating hormone; Interstitual cell stimulating hormone; Leutinizing hormone; LH; Luteinizing hormone; Lutenin; Lutenizing hormone; Ovulation test; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tri; Trip |
2.7 |
2.15 |
|
|
|
|
|
|
|
m[IU]/mL |
|
|
|
0 |
| 40374-1 |
Lutropin^1H post dose triple bolus |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Lutropin [Units/volume] in Serum or Plasma --1 hour post dose triple bolus |
|
MIN |
DefinitionDescription |
|
|
mIU/mL;IU/L |
|
|
|
|
|
|
CHAL |
|
40374-1 |
|
|
|
|
Observation |
|
|
|
0 |
LH 1h p Triple Bolus SerPl-aCnc |
|
|
|
N |
|
1 hour; 1.0Hr; 1h p Triple Bolus; 60 min; 60 minutes; 60M; 60min; After; Arbitrary concentration; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; ICSH; Interstitial cell-stimulating hormone; Interstitual cell stimulating hormone; Leutinizing hormone; LH; Luteinizing hormone; Lutenin; Lutenizing hormone; Ovulation test; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tri; Trip |
2.7 |
2.15 |
|
|
|
|
|
|
|
m[IU]/mL |
|
|
|
0 |
